Search

Your search keyword '"Lion, T"' showing total 546 results

Search Constraints

Start Over You searched for: Author "Lion, T" Remove constraint Author: "Lion, T"
546 results on '"Lion, T"'

Search Results

1. 3D-printed devices for optimized generation of cold atmospheric plasma to improve decontamination of surfaces from respiratory pathogens

2. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

Catalog

Books, media, physical & digital resources

5. Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

9. Standardization of molecular monitoring of CML : results and recommendations from the European treatment and outcome study

11. Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (Leukemia, (2019), 33, 8, (1910-1922), 10.1038/s41375-019-0413-0)

15. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

16. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

18. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR

20. PCR as a Diagnostic Tool in ALL: A Comparison Between Cytogenetic and Polymerase Chain Reaction Analysis in Pediatric Patients with Acute Lymphoblastic Leukemia

21. The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation

30. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements

31. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (vol 32, pg 345, 2019)

33. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

47. Significantly higher and more rapid cytogenetic and molecular responses can be achieved in pre-treated chronic phase CML patients with high doses of Imatinib as induction therapy (800 mg/day, 6 months) - final results of a Phase III CELSG CML11 “ISTAHIT” TRIAL: V278

50. High Dose Imatinib (800mg/day) improves Cytogenetic and Molecular Remissions in pretreated Ph+/BCR-ABL+ CML Patients in Chronic Phase; Results from the CELSG CML 11 “ISTAHIT” Phase III Study: V57